Latest news

Aplex Bio today announces the commercial launch of its Hyperplex PCR™ kits, powered by proprietary Nanopixel™ chemistry with 100-plex performance.

Discover how Hyperplex PCR™ enables 100+ target detection in a single reaction, transforming precision molecular diagnostics.

This study highlights hpPCR’s role in swift SARS-CoV-2 variant tracking in Swedish wastewater.

Revealing the latest advancements in Hyperplex PCR™ technology and a new era in genomic innovation.

Hyperplex PCR showcased at World Agri-Tech Innovation Summit 2024 as a groundbreaking solution for next-gen crop development and management.

This study highlights hpPCR’s role in swift SARS-CoV-2 variant tracking in Swedish wastewater, presented by SEEC at Epizone 2024.

Novel mRNA-Based Cell Type Identification Method to Be Showcased in Forensic Science

Aplex Bio is pleased to welcome biotech veteran Rolf Ehrnström to its Board, bolstering leadership as the company advances in the molecular testing market.

GLOWACON launched by the European Commission in Brussels last week.

Approximately 100 Swedish companies will visit CES, covering the tech and innovation space.

​

Aplex Bio receives funding from the Innovative Impact Startups autumn 2023 program

The IVA-100 list is a yearly list that recognizes top research in Sweden with high scientific value and commercial potential.

​

This study presents the learning outcomes from over two-year long monitoring of SARS-CoV-2 in Stockholm, Sweden, where hpPCR was used as proof-of-concept for variant profiling.

APLEX Bio will be pitching the international investor community at Nordic Life Science Days in Malmö, Sweden alongside 39 other startups.

Aplex Bio announces it has demonstrated superior performance of multiplexed COVID variant detection in wastewater, including the generally difficult to detect variant BA.2, using its next-generation hpPCR technology.

Sweden's Aplex Bio Gearing up to Launch 'Hyperplexed' PCR Platform

APLEX Bio announces it has raised 14 MSEK (€1.3M) for developing its massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.

APLEX Bio develops breakthrough massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.